Navigation Links
World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester

Breakthrough in Research and Treatment of Rare but Devastating Condition

LONDON, June 1, 2007-Researchers at Queen Mary University London and the University of Leicester and have today (Friday June 1) announced a potential breakthrough in the treatment of a rare but devastating medical condition that can affect children and young people.

In a world first, the clinicians and scientists from the two universities have already treated one patient with promising results. Their preliminary data are published as a letter in the New England Journal of Medicine.

This is the first time research into a condition known as "idiopathic pulmonary haemosiderosis" has investigated the role of 'oxidative stress' and it is also the first time treatment has been carried out based on the research.

Queen Mary University London and the University of Leicester have combined world-class expertise in Child Health, Pulmonary Disease and Oxidative Stress research, plus access to patients with this rare disease. This combination of factors is unique to this collaboration.

Jonathan Grigg, Professor of Paediatric Respiratory and Environmental Medicine at Queen Mary University London, said: "Idiopathic pulmonary haemosiderosis is a rare disease, the cause of which is unknown.

"Affected patients have episodes of bleeding in the lungs, which often need hospital admissions, and in some cases it can be life threatening. This is normally combated by the use of continuous oral steroids (which can have major side effects).

"In a child local to Leicester, we were able to show, for the first time, that there was high levels of oxidative stress in the lungs. In addition, we treated the increased oxidative stress by using of an antioxidant, N-acetyl cysteine - which has no side effects. Since she has been on this treatment she has had no lung bleeds, and the steroid dose has been significantly reduced."'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
2. MAP Pharmaceuticals to Present Unit Dose Budesonide Phase 2 Clinical Data at the World Asthma Meeting
3. Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
4. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
5. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
6. ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents
7. Gentiums Defibrotide Highlighted in Poster Presentation at World Congress of Nephrology
8. Onconase has Potential as Chemopreventive Agent in Mesothelioma, Reports World-Renowned Mesothelioma Researcher at AACR Annual Meeting
9. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
10. Two-Year Patient Registry Results Support Safety and Efficacy of Cypher Sirolimus-Eluting Coronary Stent in Real World Uses
11. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent

Post Your Comments:
(Date:11/9/2009)..., NATICK, Mass., Nov. 9 /PRNewswire-FirstCall/ ...ay announced its schedule of events at the 38th an...logy (AAGL), which runs from November 15-19 in Orl...will be presented featuring the Company,s Urology/...truction systems and mid-urethral sling systems us...
(Date:11/9/2009)..., NEW YORK, Nov. 9 /PRNewswire-Asia-FirstCa...E: AOB ), ("the Company" or "AOBO"), a pharmaceut... the development, manufacture and,commercializatio...unter ("OTC"),products, today announced that it pl...s on Monday, November 16, 2009, after the market c...
(Date:11/9/2009)..., SAN DIEGO, Nov. 9, 2009 /PRNewswire-FirstCall...today reported financial results for the third qua...d a lower net loss allocable to common stockholder...r $0.38 per share, compared to a net loss allocabl...008 of $56.2 million, or $0.76 per share, and a ne...
Breaking Medicine Technology:Boston Scientific's Urology/Gynecology Products Featured in Studies at Global Congress 2Boston Scientific's Urology/Gynecology Products Featured in Studies at Global Congress 3Boston Scientific's Urology/Gynecology Products Featured in Studies at Global Congress 4Boston Scientific's Urology/Gynecology Products Featured in Studies at Global Congress 5Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 2Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 3Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 4Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 5Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 6Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 7Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 8Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 9Exercise 30 Minutes a Day 3F Who Knew 21 58468 1Exercise 30 Minutes a Day 3F Who Knew 21 58468 2Boston University School of Medicines black womens health study receives 249 1 million award 58465 1Book by UCR biologist tells story of 100 year quest for elusive malaria vaccine 58462 1Book by UCR biologist tells story of 100 year quest for elusive malaria vaccine 58462 2Book by UCR biologist tells story of 100 year quest for elusive malaria vaccine 58462 3Book by UCR biologist tells story of 100 year quest for elusive malaria vaccine 58462 4
(Date:11/9/2009)...wswire/ -- Sutter Health, a family of doctors, not...e providers, is donating $255,000 to food banks ac...banks will share the quarter-million-dollar donati...thousands of families across the north state. ,... with and supporting charitable programs and servi...
(Date:11/9/2009)...gs that inhibit estrogen, , , MONDAY, N...breast cancer and osteoporosis eliminated cervical...e drugs also cleared precancerous growths in the c...r in mice with precancerous lesions. , The brea...steoporosis drug raloxifene were given to mice gen...
(Date:11/9/2009)...conditions are age-related, researchers say , ...t surgery doesn,t appear to speed the progression ...ng to a new study that challenges the belief that ...r. , "Because both conditions are strongly age-...AMD," wrote Li Ming Dong, of Stony Brook Universit...
(Date:11/9/2009)...ire-FirstCall/ - Hard To Treat Diseases (HTDS.PK) ...is, a US$41 billion international healthcare compa...e partner, Zhejiang Tianyuan Bio-Pharmaceutical Co...nd will begin a five-year, $1 billion China initia...increase its investment in its China R&D facil...
(Date:11/9/2009)...r Network (NCCN) has posted a draft white paper fo... near-term comparative effectiveness clinical eval...roduces the NCCN Comparative Therapeutic Index(TM)...e risk-versus-benefit of different treatment optio...lines in Oncology(TM). The paper will be posted fo...
Breaking Medicine News(10 mins):Health News:Sutter Health Donates $255,000 to Help the Hungry This Holiday Season 2Health News:Breast Cancer Drugs May Fight Cervical Cancer, Too 2Health News:Cataract Surgery Doesn't Worsen Macular Degeneration: Study 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 4Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 2Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 3Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 4
...n Medical School, an injectable gel may be useful ... neck squamous cell carcinoma affects about 20,000...rug cisplatin has been shown to be an effective th...died 120 patients who were previously treated for ...
...found that eating more calories and fats may incre...some people. Previous research has shown that mice.... //Researchers feel this is because of fewer dest...se the damage done by particles found in brains of...
...bout life may not only help you live longer, it ma...he University of Illinois, found two years ago tha...same group of researchers// looked to see if one's...ermined who was optimistic, pessimistic or a mixtu...
...eneficial to our body. When sweet corn is heated, ..., and thereby making it a very healthy addition to...onception that boiling or steaming vegetables and ...nt power than you lose on cooking. For vitam...
...ely poor diet, which adds to the health risks of p...hand smoke accounts for up to 24 per cent of lung ...e smoking - usually because they live with a smoke...in their new survey, that many people living with ...
...because they really don't have allergies," said Sh...of pharmacy at Ohio State University. "They're oft...roblem."// A recent study of 246 patients showed ...rgies; the blood samples from only 35 percent of t...
Other Medicine News:Health News:Diet combined to Alzheimer's disease 2
EBI OsteoGen™-M (Mesh Cathode)
Interference Screws
...crew is indicated for graft fixation in Orthopaedi...s with bone-patellar tendon-bone or soft tissue au...es easy and atraumatic insertions with excellent g...-Reinforced 96L/4D copolymer combines optimal stre...
PHANTOM SofThread Cannulated Interference Screws
Medicine Products: